CJC-1295 (No DAC) 5MG

CJC-1295 (No DAC) 5MG

CJC-1295 (No DAC) 5MG

$70.00

CJC-1295 without DAC works by mimicking the action of GHRH. When administered, it binds to GHRH receptors in the pituitary gland, which leads to an increase in the secretion of growth hormone. This increase in growth hormone can result in various physiological benefits, including muscle growth, fat loss, and improved recovery times.

Only 16 left in stock

Category:

Overview

CJC-1295 (No DAC) is the tetrasubstituted analog of GHRH (1-29)-NH₂ (often called MOD-GRF (1-29)) engineered to improve stability against DPP-IV cleavage while retaining short, pulse-like pharmacodynamics seen with native GHRH (1-29)/Sermorelin. Unlike the DAC-conjugated version, No-DAC does not bind albumin, keeping the half-life short (minutes) and supporting discrete GH pulses—a feature widely leveraged in endocrine and metabolism research. [3][4][7][8][16]

  • Receptor & pathway: Binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, activating Gs → adenylyl cyclase → cAMP → PKA → CREB signaling to trigger GH synthesis and secretion. [12][13][17]
  • Pulsatility matters: Research shows pulsatile GH release is preserved (and physiologically desirable) versus sustained elevation; No-DAC analogs are commonly used to model physiologic pulses. [11][16]
  • Synergy: Co-stimulation with GHRPs (e.g., ipamorelin) is synergistic, often used to model near-maximal GH secretory capacity without overriding negative feedback. [14][15][24]

Molecular/Design Notes

  • Backbone: GHRH(1-29)-NH₂ analog (a.k.a. Sermorelin backbone) with four substitutions to reduce DPP-IV and trypsin-like degradation. [3][5][18]
  • No DAC: Lacks the Drug Affinity Complex—no albumin tethering, no multi-day exposure (that profile is specific to DAC-CJC-1295). [1][11]

Typical Research Use Cases (in-vitro)

  • Somatotroph signaling & GH pulsatility models
  • Endocrine-metabolic crosstalk (GH → IGF-1 axis, lipolysis)
  • Comparative studies: No-DAC pulse vs DAC sustained profiles
  • Combination paradigms: GHRH analog + GHRP synergy mapping [14][15][24]

 

SKU note: This product is offered in 5 mg and 10 mg formats to fit protocol design and customizable dosing needs for lab testing (e.g., titration experiments). For research purposes only – CJC-1295 peptide.

Disclaimer (expanded)

All compounds and information provided by Regenerative Health Peptides are intended exclusively for laboratory research and educational purposes. Products are not medications and are not for human or animal use, including but not limited to diagnosis, treatment, cure, or prevention of any disease. Items are tested for purity, ID, and labelled in the USA and supplied for in-vitro studies only. Researchers are responsible for compliance with all applicable regulations.

Background & Rationale

  • Long-acting GHRH analog (DAC variant) evidence: Early clinical investigations with DAC-CJC-1295 established durable increases in GH/IGF-1 and showed pulsatility persists despite continuous receptor stimulation—useful contrast for No-DAC pulse models. 1 11 15
  • Why No-DAC? DPP-IV rapidly cleaves native GHRH; tetrasubstitution enhances stability but keeps exposure short, enabling discrete pulse studies closer to physiology. 3 5 7 8 18

Key Findings & Methods Supporting No-DAC Use

  1. Teichman et al.: Long-acting CJC-1295 increases GH/IGF-1 (context for comparative pulse vs. sustained designs). 
  2. Ionescu et al.: Pulsatile GH secretion persists under prolonged GHRH-R stimulation (physiology preserved).
  3. Frohman et al.: DPP-IV is the primary plasma protease degrading GHRH; rationale for DPP-IV-resistant analogs.
  4. Mulvihill & Drucker: Comprehensive review of DPP-4 biology impacting peptide hormones (GHRH among substrates).
  5. Martin et al.: DPP-IV cleavage mapping on GRF analogs; substitution effects. 
  6. Rafferty et al.: GHRH(1-29) analogs: plasma half-life minutes; supports short-acting profile.
  7. Soule et al.: D-Ala² substitution extends half-life and reduces clearance in men.
  8. Aitman et al.: Native vs agonist GHRH(1-29)-NH₂—similar peak GH at submaximal dosing.
  9. Spoudeas et al.: Dose–response to GHRH(1-29)-NH₂ (low-dose testing).
  10. Cohen et al.: GHRH-R → cAMP/PKA/CREB transcriptional control in somatotrophs.
  11. Ivanova et al.: cAMP in pituitary—central to GH transcription/release.
  12. Olarescu & Jørgensen: Normal GH physiology and pulsatility.
  13. Vijayakumar et al.: GH in metabolism (lipolysis, IGF-1 axis).
  14. Bowers 1990: GHRH + GHRP → synergy in GH release (independent mechanisms).
  15. Bowers et al. 2004: Sustained pulsatile GH with GHRH + GHRP-2 combined stimuli.
  16. Peroni et al.: GHRP-2 actions on somatotrophs; secretagogue physiology.
  17. Sigalos et al.: Safety/efficacy of GHS; synergy with GHRH highlighted.
  18. Knoop et al.: Analytical identification of GHRH analogs (incl. CJC-1295) and metabolites.
  19. Memdouh et al.: Detection of sermorelin, tesamorelin, CJC-1295 variants—analytical context for labs.
  20. Timms et al.: LC-MS/MS confirmation of CJC-1295 in equine plasma.
  21. Khorram et al.: Nightly GHRH analog activates somatotropic axis in older adults (physiology reference).
  22. Khorram et al.: Immune effects of GHRH analogs in aging men.
  23. Maheshwari et al.: GH pulsatility persists even with altered GHRH-R signaling.
  24. Paulo et al.: Two-peptide synergy (GHRH + GHRP-2) in secretion testing.
  25. Halmos et al.: GHRH-R signaling pathways (updated mechanistic review).

Note: Items 1–2 describe DAC-CJC-1295 to contextualize No DAC pulse vs DAC sustained paradigms (useful in comparative lab designs). All citations are peer-reviewed resources relevant to GHRH analog design, signaling, pulsatility, DPP-IV degradation, and analytical detection.

Peptide storage

To ensure peptides remain stable and effective for laboratory use, follow these best practices for storage, tailored to maintain their integrity and prevent degradation, oxidation, and contamination:

Short-Term Storage

  • Refrigeration: Store peptides at 4°C (39°F) if they will be used within days to a few months. Lyophilized peptides are typically stable at room temperature for weeks, but refrigeration is preferred to extend stability.
  • Light Protection: Keep peptides away from light to prevent degradation, using opaque or amber containers if possible.

Long-Term Storage

  • Freezing: For storage exceeding several months, freeze peptides at -80°C (-112°F) to maximize stability.
  • Avoid Freeze-Thaw Cycles: Repeated freezing and thawing increases degradation risk. Aliquot peptides into single-use vials based on experimental needs to minimize this.
  • Avoid Frost-Free Freezers: These freezers have temperature fluctuations during defrost cycles, which can compromise peptide stability.

Preventing Oxidation and Moisture Contamination

  • Minimize Air Exposure: Limit the time peptide containers are open to reduce oxidation, especially for peptides containing cysteine (C), methionine (M), or tryptophan (W), which are prone to air oxidation.
  • Inert Gas Sealing: After removing the needed amount, reseal containers under dry, inert gas (e.g., nitrogen or argon) to prevent oxidation of remaining peptides.
  • Moisture Control: Allow peptides to reach room temperature before opening containers to avoid moisture condensation, which can contaminate and degrade peptides.

Storing Peptides in Solution

  • Avoid Long-Term Storage in Solution: Peptide solutions have a shorter shelf life and are susceptible to bacterial degradation. Lyophilized form is preferred for long-term storage.
  • Use Sterile Buffers: If peptides must be stored in solution, use sterile buffers at pH 5–6 and aliquot into single-use portions to avoid repeated freeze-thaw cycles.
  • Refrigeration for Solutions: Store solutions at 4°C (39°F) for 30–60 days. Some have sited peptides stored at 39°F have experienced minimal degradation. Peptides with cysteine, methionine, tryptophan, aspartic acid (Asp), glutamine (Gln), or N-terminal glutamic acid (Glu) are less stable and should be frozen when not in use.

Peptide Storage Containers

  • Container Requirements: Use clean, clear, structurally sound, and chemically resistant containers sized appropriately for the peptide quantity.
  • Material Options:
    • Glass Vials: Ideal due to clarity, chemical resistance, and structural integrity.
    • Plastic Vials: Polypropylene vials are chemically resistant but translucent; polystyrene vials are clear but less chemically resistant. Transfer peptides to glass if needed.
  • Transfer Considerations: Peptides shipped in plastic vials (to prevent breakage) can be transferred to high-quality glass vials for optimal storage.

General Tips

  • Store in a cold, dry, dark environment.
  • Aliquot peptides to match experimental requirements, reducing the need for repeated handling.
  • Avoid light exposure to prevent photodegradation.
  • Minimize air exposure to reduce oxidation risks.
  • Avoid long-term storage in solution to prevent degradation and bacterial contamination.

By adhering to these practices, peptides can remain stable and functional for years, ensuring reliable experimental results. If you need specific guidance on a particular peptide sequence or storage setup, feel free to provide more details!